NEW YORK – Stockholm-based Devyser said this week that the firm has been awarded a tender with University Hospital in Bologna for the firm's genotyping tests that are used for cystic fibrosis screening and confirmation in newborns and adults. The tender is valid for three years and covers use of Devyser's CE-IVD labeled CFTR fragment analysis tests for detection of sequence variants in the cystic fibrosis transmembrane conductance regulator gene. The firm said in a statement that the order value is estimated to be about SEK 2 million ($191,600) per year.
Abbott said this week its board has increased the company's quarterly dividend to $.55 per share. The dividend is payable on Feb. 15, 2024, to shareholders of record at the close of business on Jan. 12, 2024.
Virax Biolabs Group announced this week that its shareholders have approved a proposed 1-for-10 share consolidation of its ordinary shares of $.0001 par value each. Every 10 issued and outstanding ordinary shares of a par value of $.0001 each will automatically be consolidated into one issued and outstanding ordinary share of a par value of $.001 each. On Dec. 18, the firm’s ordinary shares will begin trading on a post-share consolidation basis on the Nasdaq Capital Market under the same VRAX ticker but with a new CUSIP number. The share consolidation is intended to help the company regain compliance with Nasdaq requirements and maintain its listing, the firm said in a statement.
DnaNudge announced this week that is has received medical device approval from the Ghana Food and Drugs Authority for its four-in-one molecular diagnostic assay for respiratory viruses and a point-of-care instrument. The RT-PCR test detects SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus in approximately one hour using the firm's NudgeBox portable analyzer system. DnaNudge's commercialization partner, NantNudge, will now roll out the point-of-care technology across Africa, beginning in Ghana.
UK-based pharma firm PharmaKure said this week that it has entered a research collaboration with pharmacy faculty at Malaysia’s Universiti Teknologi MARA (UiTM) for the development of PharmaKure’s AlzmetrixTM test, a blood-based assay that uses machine learning to identify individuals at high risk of developing Alzheimer’s disease. According to the company, the deal will allow it to partner with UiTM experts to supplement its in-house expertise in the analysis of molecular signatures for the disease.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.